Device Trial Radar · NCT05742997
Evaluation of a Novel Diagnostic Kit for the Detection of Placental Alpha-Microglobulin-1 in the Prediction of Preterm Birth in Women Presenting With Signs and Symptoms of Preterm Labor
Last checked: Nov 20, 2026Latest source record: Feb 24, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
165
Planned (sponsor's estimate)
Start
Oct 1, 2021
Primary completion
Aug 31, 2023
Study completion Oct 31, 2023
Sponsor
- Lead sponsor
- Ziekenhuis Oost-LimburgAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Feb 24, 2023
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated device
- No
- Who can join
- Female only, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Currently, the American College of Obstetricians and Gynecologists (ACOG) indicate in their most recent Practice Bulletin on the Management of Preterm Labor that many tests to identify women at risk of preterm birth have been proposed and evaluated; however, only ultrasonography and fetal fibronectin testing have been shown to have benefit. Ultrasonography to determine cervical length, fetal fibronectin testing, or a combination of both may be useful in determining which women are at high risk for preterm delivery. However, their clinical usefulness may rest primarily with their ability to identify women who are least likely to deliver (i.e. their negative predictive value). Therefore, there is an urgent need for a test with a high positive predictive value in order to accurately predict imminent delivery to allow for salutary intervention.
Conditions
- Preterm Birth
Interventions
PartoSureDevice
Diagnostic Kit for the Detection of Placental Alpha-Microglobulin-1
Fetal FibronectineDevice
Diagnostic Kit for the Detection of Fetal Fibronectine
Primary outcomes
What the sponsor says the trial is designed to measure.
- Sensitivity (SN), specificity (SP), positive predictive value (PPV) and negative predictive valueTime frame: 48 hours
- Sensitivity (SN), specificity (SP), positive predictive value (PPV) and negative predictive valueTime frame: 7 days
- Sensitivity (SN), specificity (SP), positive predictive value (PPV) and negative predictive valueTime frame: 14 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Ziekenhuis Oost-Limburg
Genk, Limburg, Belgium · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.